A comparison of cardiac troponin T and cardiac troponin I in patients with acute coronary syndromes.
The majority of studies have shown that the performance of assays for cTnT and cTnI is almost identical in detecting AMI in patients with coronary artery disease. Currently cTnT may have an advantage over cTnI because available laboratory and POC platforms are standardized to a single reference material. Nevertheless, the decision to use cTnT or cTnI a given laboratory will probably be made on the basis of cost and the availability of automated instrumentation within that institution, and not necessarily on assay performance. A laboratory is unlikely to purchase an instrument to perform a single test. Because cTnI will soon be available on all commercial immunoassay analyzers, it seems likely that cTnI will become the analyte of choice.